Table 3:

Exposure-adjusted rates (per 100 patient-year) of thromboembolic events

	Ruxolitinib rate (n=110)*			Best available therapy rate (n=111)†			Crossover rate (n=98)‡
	All grades	Grade 1 or 2	Grade 3 or 4	All grades	Grade 1 or 2	Grade 3 or 4	All grades	Grade 1 or 2	Grade 3 or 4
All thromboembolic events	5 (1·2)	2 (0·5)	3 (0·7)	6 (8·2)	4 (5·5)	2 (2·7)	9 (2·7)	4 (1·2)	5 (1·5)
Cerebral infarction	1 (0·2)	0	1 (0·2)	0	0	0	0	0	0
Ischaemic stroke	1 (0·2)	1 (0·2)	0	0	0	0	1 (0·3)	0	1 (0·3)
Transient ischaemic attack	0	0	0	0	0	0	2 (0·6)	0	2 (0·6)
Portal vein thrombosis	1 (0·2)	0	1 (0·2)	0	0	0	0	0	0
Pulmonary embolism	1 (0·2)	0	1 (0·2)	1 (1·4)	0	1 (1·4)	0	0	0
Retinal vascular thrombosis	1 (0·2)	1 (0·2)	0	0	0	0	0	0	0
Myocardial infarction	0	0	0	0	0	0	2 (0·6)	1 (0·3)	1 (0·3)
Acute myocardial infarction	0	0	0	1 (1·4)	0	1 (1·4)	0	0	0
Deep vein thrombosis	0	0	0	2 (2·7)	1 (1·3)	1 (1·4)	1 (0·3)	1 (0·3)	0
Thrombophlebitis	0	0	0	1 (1·4)	1 (1·4)	0	1 (0·3)	1 (0·3)	0
Thrombosis	0	0	0	1 (1·4)	1 (1·4)	0	1 (0·3)	1 (0·3)	0
Bone infarction	0	0	0	0	0	0	1 (0·3)	1 (0·3)	0
Coronary artery occlusion	0	0	0	0	0	0	1 (0·3)	1 (0·3)	0
Disseminated intravascular coagulation	0	0	0	0	0	0	1 (0·3)	0	1 (0·3)
Splenic infarction	0	0	0	1 (1·4)	1 (1·4)	0	0	0	0

Data are n (rate). Adjusted rates were calculated as the number of patients with events per 100 patient-year of exposure. Events occurring at a rate of 0・2 per 100 patient-years of exposure in any group. MedDRA version 19.1 was used to code the events.

^*Exposure=428 4 patient-years.

^†Exposure=73 6 patient-years.

^‡Exposure=329 9 patient-years.